Status:
NOT_YET_RECRUITING
68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois
Conditions:
Pancreatic Adenocarcinoma
PET / CT
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical study investigates the use of a new imaging technique called 68Ga-FAPI-46 PET/CT in people with pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its rapid progression,...
Detailed Description
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly types of cancer. It often develops without clear symptoms and is usually diagnosed at a late stage, when treatment opti...
Eligibility Criteria
Inclusion
- Age ≥18 years.
- Karnofsky index ≥80%.
- Operable or operable borderline tumor after neoadjuvant chemotherapy response
- Planned surgical tumor resection.
- SOC imaging (ceCT and MRI) performed as pre-surgery exams.
- Signed informed consent.
Exclusion
- Pregnancy or breastfeeding.
- Claustrophobia.
- Severe renal insufficiency (GFR\<30 mL/min/1.73m²).
- Liver enzymes (ALAT, ASAT \>5× the upper limit).
- Bilirubin \>3× the upper limit.
- Hemoglobin \<8 g/dL.
- Absolute neutrophil count \<1000/mm³.
- Platelets \<75,000/µL.
- Inability to give informed consent or follow study procedures.
- The patient refuses to receive information regarding incidental findings.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06911021
Start Date
May 1 2025
End Date
December 31 2027
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011